http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Erkan Unsal,Kadir Eltutar,Pınar Sultan,Sezin Ozdogan Erkul,Ozen Ayranci Osmanbasoglu 대한안과학회 2017 Korean Journal of Ophthalmology Vol.31 No.2
Purpose: To evaluate the safety and efficacy of intravitreal dexamethasone (IVD) implants in eyes with diabeticmacular edema that did not respond to previous treatment. Methods: We included 46 eyes of 46 patients in this retrospective study. Each month, we recorded patient visualacuity with logarithm of the minimum angle of resolution using the Early Treatment Diabetic RetinopathyStudy chart, central macular thickness measurements with optical coherence tomography, intraocular pressure(IOP), and posttreatment complication occurrence. Results: The mean follow-up time was 8.95 ± 1.33 months (range, 6 to 12). Best-corrected visual acuity improvedsignificantly in the first 4 months after IVD, but no statistically significant change was observed over the following2 months. Although a statistically significant decrease in central macular thickness was observed in thefirst 3 months, the change was not statistically significant in the following 3 months. There was a statisticallysignificant increase in IOP in the first 2 months, but no statistically significant change was observed in the followingmonths. IOP was controlled with medication in all patients with elevated IOP. Of the 26 phakic patients,two had cataracts requiring surgery. Conclusions: Cases of refractory diabetic macular edema that did not respond to previous treatment, such asanti-vascular endothelial growth factor injections and laser photocoagulation, exhibited improvements in visualacuity and decreases in retinal thickness after IVD implantation. Both functional and anatomical effects wereobserved in the first 3 months after injection. Repeat injections and frequent examination might be required forcontinued improvement. Side effects, such as cataracts and elevation of IOP, may require medical or surgicaltreatment.
Meltem Gungor,Ergul Belge Kurutas,Erkan Oner,Velid Unsal,Hatice Altun,Ali Erdinc Yalin,Serap Yalin,Ozlem Bozkus,Nilfer Sahin 대한정신약물학회 2021 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.19 No.3
Objective: Attention deficit hyperactivity disorder (ADHD) is a heterogeneous, highly heritable, a common childhood neurobehavioural disorder resulting from complex gene-gene and gene-environment interactions. The erythropoietin (Epo)/erythropoietin receptors (EpoR) system turned out to have additional important functions in nonhematopoietic tissue. In this study, we aimed to investigate the levels of Epo and and EpoR, and also their diagnostic values in children with ADHD. Methods: A total of 70 children were included in the study, 35 drug-naive patients with ADHD (age: 6−12 years; male/female: 20/15) and 35 healthy controls (age: 6−12 years; male/female: 22/13). Serum Epo and EpoR levels was determined using a commercial sandwich enzyme-linked immunosorbent assay kit. Results: The results indicated that the levels of Epo decreased in patients with ADHD compared to control (p < 0.05). On the other hand, EpoR levels increased in these patients (p < 0.05). Furthermore, the ratio of Epo/EpoR was significantly lower in ADHD patients than controls (p < 0.05). Receiver operator characteristic curve analysis showed high diagnostic performance for Epo and EpoR, areas under curve were 0.980 and 1.000, respectively. Conclusion: This is the first report to investigate the association between serum Epo and EpoR levels in ADHD patients. Our results indicated that Epo may play a role in the etiology of ADHD, and Epo therapy may be beneficial in these disorders if given in addition to the routine treatment of children with ADHD. Furthermore, our results reveal possible diagnostic value of Epo and EpoR.